Corvus Pharmaceuticals (CRVS) Current Assets (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Current Assets of $239.9 million for Q1 2026, up 427.46% year-over-year from $45.5 million in Q1 2025, and up 312.18% quarter-over-quarter from $58.2 million in Q4 2025.
Corvus Pharmaceuticals (CRVS) Current Assets (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $239.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 427.46% year-over-year to $239.9 million; the TTM figure through Mar 2026 stood at $239.9 million (up 427.46% YoY), while the FY2025 annual figure was $58.2 million, up 7.0% from the prior year.
- Current Assets for Q1 2026 stood at $239.9 million, up from $58.2 million in the prior quarter.
- The five-year high for Current Assets was $239.9 million in Q1 2026, with the low at $22.9 million in Q1 2024.
- The 5-year median for Current Assets is $48.3 million (2024), against an average of $59.3 million.
- The sharpest annual moves came in 2023 and 2026: Current Assets sank 44.77% in 2023, then jumped 427.46% in 2026.
- Corvus Pharmaceuticals' Current Assets stood at $43.7 million in 2022, then sank by 35.97% to $28.0 million in 2023, then surged by 94.62% to $54.4 million in 2024, then climbed by 7.0% to $58.2 million in 2025, then soared by 312.18% to $239.9 million in 2026.
- Business Quant data shows CRVS's Current Assets at $239.9 million in Q1 2026, $58.2 million in Q4 2025, and $66.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 220.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220.97 Mn |
| Mar 31, 2026 | 239.95 Mn |
| Dec 31, 2025 | 58.21 Mn |
| Sep 30, 2025 | 66.94 Mn |
| Jun 30, 2025 | 75.78 Mn |
| Mar 31, 2025 | 45.49 Mn |
| Dec 31, 2024 | 54.41 Mn |
| Sep 30, 2024 | 42.92 Mn |
| Jun 30, 2024 | 48.26 Mn |
| Mar 31, 2024 | 22.85 Mn |
| Dec 31, 2023 | 27.96 Mn |
| Sep 30, 2023 | 33.09 Mn |
| Jun 30, 2023 | 37.91 Mn |
| Mar 31, 2023 | 35.55 Mn |
| Dec 31, 2022 | 43.66 Mn |
| Sep 30, 2022 | 51.27 Mn |
| Jun 30, 2022 | 58.89 Mn |
| Mar 31, 2022 | 64.37 Mn |
| Dec 31, 2021 | 71.31 Mn |
| Sep 30, 2021 | 78.76 Mn |